Skip to main content

VYVANSE (Shire Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
242 working days (255)
Active ingredients
lisdexamfetamine dimesilate
Registration type
VYVANSE is now also indicated for the treatment of moderate to severe Binge Eating Disorder (BED) in adults when nonpharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.

Help us improve the Therapeutic Goods Administration site